LAUSR

A 20-year-old man presented with chest pain started on the 3th day of his first dose of mRNA coronavirus disease 2019 (COVID-19) Vaccine (BNT162b2). On presentation, the patient’s temperature was 37.6 C, blood pressure was 110/60mmHg, oxygen saturation was 98% on room air. Physical examination was unremarkable. The initial electrocardiogram showed sinus rhythm at 90 bpm with 1-mm diffuse ST-segment elevation. Laboratory evaluation showed a white blood cell count of 11 10/mL (normal 4–10 10), elevated high-sensitivity troponin T of 15,000 ng/L (normal 0– 47), N-terminal pro-B-type natriuretic peptide (NTproBNP) of 550 ng/L (normal < 110) and C-reactive protein level of 65mg/L. Other blood tests including renal, hepatic and coagulation panel were normal. Transthoracic echocardiography (TTE) showed no regional wall motion abnormalities or pericardial effusion. However, there was a round shaped fresh thrombus-like mass attached to the apical segment of anteroseptal wall.